According to the Zhitong Finance App, China Regenerative Medicine (08158) announced its 2026 interim results, with revenue of HK$41.734 million, up 52.36% year on year; net profit of HK$4.623 million, which is basically the same; profit per share of HK 1.51 cents.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.